

PRESENTATION TYPES:

Featured Research Sessions

Oral Sessions

Posters

Other Activities

Collaborations

 **FEATURED RESEARCH SESSIONS**

Tuesday, **July 28, 7:30 AM** / 7:55 AM (CT)

Emerging beta-amyloid pathology is associated with tau, synaptic, neurodegeneration and gray matter volume differences.

Presenting author

Jose Luis Molinuevo, MD, PhD

Session details: ODFRS2-09-04, SCR2-06

The value of amyloid PET beyond dichotomization.

Tuesday, **July 28, 11:00 AM** / 11:25 AM (CT)

Polygenic-wide analysis to assess the impact of genetic risk profiles on brain morphometry in the ALFA study.

Presenting author

Natalia Vilor-Tejedor, PhD

Session details: ODFRS2-03-03, SCR2-15

Early imaging changes in cognitively normal subjects at risk of late onset AD.

Tuesday, **July 28, 11:00 AM** / 11:25 AM (CT)

Impact of the ApoE gene on amyloid deposition in participants with abnormal soluble amyloid levels.

Presenting author

Raffaele Cacciaglia, PhD

Session details: ODFRS2-03-04, SCR2-15

Early imaging changes in cognitively normal subjects at risk of late onset AD.

 **ORAL SESSIONS**

Tuesday, **July 28, 6:30 AM** / 6:55 AM (CT)

The effect of physical activity on CSF biomarkers of Alzheimer's disease differs between men and women.

Presenting author

Marta Milà-Alomà, MSc

Session details: ODO2-01-04, SCR2-01

Biomarkers (non-neuroimaging): Alzheimer's Disease Incidence, Risk Factors and Biomarkers.

Wednesday, **July 29, 8:30 AM** / 8:55 AM (CT)

Amyloid positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relates to hippocampal volume.

Presenting author

Gonzalo Sánchez-Benavides, PhD

Session details: ODO3-09-05, SCR3-08

Neuropsychiatry and Behavioral Neurology: The Neuropsychiatry Of Subjective Cognitive Disorder And Prodromal AD.

Thursday, **July 30, 8:30 AM** / 8:55 AM (CT)

Air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals.

Presenting author

Marta Crous-Bou, PhD

Session details: ODO4-10-05, SCR4-09

Epidemiology: Effects Of Air Pollution On Cognition.

Thursday, **July 30, 11:30 AM** / 11:55 AM (CT)

Weight loss predicts Alzheimer's disease biomarker positivity in cognitively unimpaired middle-aged adults.

Presenting author

Oriol Grau-Rivera, MD, PhD

Session details: ODO4-08-04, SCR4-17

Epidemiology: Cardiovascular Risk Factors.



POSTERS

Monday, July 27, 12 AM (CT)

Session details: **P1 [Alzheimer's Imaging Consortium]** Amyloid Imaging.

Impact of APOE-ε4 on cerebral amyloid deposition in participants with abnormal soluble amyloid levels. POSTER #45828

Presenting author: Raffaele Cacciaglia, PhD

Monday, July 27, 12 AM (CT)

Session details: **P1 [Basic Science and Pathogenesis]** Human Neuropathology / Imaging-pathologic correlations.

White matter microstructure and cerebrospinal fluid biomarkers of Alzheimer's disease in middle-aged cognitively unimpaired participants (the ALFA Study). POSTER #43027

Presenting author: Greg Operto, PhD

Tuesday, July 28, 12 AM (CT)

Session details: **P2 [Biomarkers]** Neuroimaging / Optimal neuroimaging measures for early detection.

Multiple biological pathways associate with cerebral amyloid load in the early Alzheimer's continuum. POSTER #44733

Presenting author: Gemma Salvadó, MSc

Proximity to parental age at onset exacerbates amyloid burden while mental conditions exacerbate neural loss during midlife. POSTER #45171

Presenting author: Eider Arenaza-Urquijo, PhD

Tuesday, July 28, 12 AM (CT)

Session details: **P2 [Biomarkers]** Neuroimaging / Optimal neuroimaging measures for tracking disease progression.

Harmonization of Amyloid PET Scans Minimizes the Impact of Reconstruction Parameters on Centiloid Values. POSTER #45294

Presenting author: Mahnaz Shekari, MSc

***** This poster has been selected for the ISTAART Student Science Spotlight program.

Tuesday, July 28, 12 AM (CT)

Session details: **P2 [Biomarkers]** Neuroimaging / Multi-modal comparisons.

Higher fronto-parietal metabolism parallels a greater impact of amyloid and anxiety on medial temporal areas in women versus men. POSTER #44780

Presenting author: Eider Arenaza-Urquijo, PhD

 This poster will be also presented on **Aug 10, 8 AM (CT)** in the **ISTAART webinar: 'Reserve, Resilience and Protective Factors'**

Multiple Pathophysiological Biomarkers are Associated with Gray Matter Volume and Cerebral Glucose Metabolism in the Early Preclinical Alzheimer's Continuum. POSTER #44808

Presenting author: Juan Domingo Gispert, PhD

Tuesday, July 28, 12 AM (CT)

Session details: **P2 [Biomarkers]** Neuroimaging / Imaging and genetics.

Differential effects of APOE2 and APOE4 alleles on PET-measured amyloid-β and tau deposition in older individuals without dementia. POSTER #40440

Presenting author: Gemma Salvadó, MSc

APOE-ε4 shapes temporo-parietal networks properties in middle age cognitively unimpaired individuals: a graph theory analysis. POSTER #45092

Presenting author: José María González de Echevarri, PhD

Tuesday, July 28, 12 AM (CT)

Session details: **P2 [Biomarkers]** Biomarkers (non-neuroimaging) / Novel biomarkers.

Amyloid-β, tau, synaptic, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimer's continuum. POSTER #44444

Presenting author: Marc Suárez-Calvet, MD, PhD

Wednesday, July 29, 12 AM (CT)

Session details: **P3 [Clinical Manifestations]** Neuropsychiatry and Behavioral Neurology / Assessment/measurement of neuropsychiatric/behavioral and psychological symptoms.

Subjective cognitive decline correlates with medial temporal lobe and hippocampal subfield volumetry in cognitively unimpaired participants. POSTER #43520

Presenting author: Greg Operto, PhD



POSTERS

Wednesday, July 29, 12 AM (CT)

Session details: **P3 [Clinical Manifestations]** Neuropsychiatry and Behavioral Neurology / Presymptomatic disease/prodromal disease/prodromal states.

Incidence of Subjective Cognitive Decline is associated to amyloid- β pathology, whereas stability relates to neurodegeneration. POSTER #45293

Presenting author: Gonzalo Sánchez-Benavides, PhD

Thursday, July 30, 12 AM (CT)

Session details: **P4 [Public Health]** Prevention (nonpharmacological) / Multidomain.

PENSA Study: study design, recruitment profiles and participants inclusion in multimodal intervention studies. POSTER #45074

Presenting author: Iva Knezevic, PhD

Thursday, July 30, 12 AM (CT)

Session details: **P4 [Public Health]** Epidemiology / Innovative methods in epidemiology (i.e. assessment methods, design, recruitment strategies, statistical methods, etc).

Genetically predicted telomere length and Alzheimer's disease endophenotypes: a Mendelian randomization study. POSTER #44720

Presenting author: Marta Crous-Bou, PhD

The BarcelonaBeta Dementia Prevention Research Clinic: study design, recruitment profiles and inclusion in prevention studies (update). POSTER #45800

Presenting author: Karine Fauria, PhD

ALFA+: a cohort study to understand and model the preclinical stage of Alzheimer's disease. POSTER #45935

Presenting author: Carolina Minguillón, PhD



OTHER ACTIVITIES

José Luis Molinuevo, MD, PhD, is a committee member of the AAIC 2020. He will also participate in the Global Biomarkers Standardization Consortium (GBSC) AAIC 2020 Meeting, the WW FINGERS Meeting AAIC 2020, and the *Alzheimer's & Dementia* editors meeting.



COLLABORATIONS

Featured Research Sessions

ODFRS2-09-02 Examining Centiloid quantification against visual assessment using [18F]flutemetamol PET.

ODFRS2-09-04 Emerging beta-amyloid pathology is associated with tau, synaptic, neurodegeneration and gray matter volume differences.

ODFRS2-09-01 A multi-study analysis of the spatial-temporal progression of amyloid deposition and its utility for longitudinal studies.

ODFRS2-09-03 Converging evidence for a "gray-zone" of amyloid burden and its relevance.

Oral Sessions

ODO2-06 Discordant results in CSF/PET A β biomarkers are dependent on APOE genotype and related to inter-individual differences in CSF A β 42, A β 40 and A β 38 isoforms.

Posters

Poster #37912 Operationalization of the ATN classification scheme in preclinical AD: findings from EPAD v500.0 Data Release.

Poster #43157 A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol PET images.

Poster #40447 Use of the Medtep digital health platform in the framework of a multimodal intervention in patients with subjective cognitive decline (PENSA Study).

Poster #41952 ExploreQC: A toolbox for MRI quality control in the EPAD multicentre study.

Poster #42623 Dynamic PET imaging reduces sample sizes to detect longitudinal amyloid accumulation.

Poster #42628 Baseline features of the AMYPAD Diagnostic and Patient Management Study (DPMS) participants.

Poster #42998 A co-creation approach to design the implementation of a multimodal

intervention in patients with subjective cognitive decline (PENSA Study).

Poster #43562 The effect of mindfulness-based programs on cognitive performance across the lifespan: a systematic review and meta-analysis.

Poster #44711 Current Status and Quantitative Results of the AMYPAD Prognostic and Natural History Study.

Poster #44739 Amyloid-dependent association of Grey Matter Network disruptions with Phospho-Tau in preclinical Alzheimer's disease.

Poster #45240 Between-country harmonization and differences of the Lifetime of Experiences Questionnaire (LEQ) for lifespan complex mental activity assessment.

Poster #45905 Cross-modal associations between traditional and emerging CSF biomarkers and grey matter network disruption in autosomal dominant Alzheimer disease.

Poster #47209 International Initiative for Harmonization of Cerebrospinal Fluid Diagnostic comments in Alzheimer's Disease.